OSTEOGENESIS IMPERFECTA TREATMENT MARKET ANALYSIS

Osteogenesis Imperfecta Treatment MarketSize and Trends

Global osteogenesis imperfecta treatment market is estimated to be valued at US$ 722.8 million in 2023 and is expected to exhibit a CAGR of 2.4% during the forecast period (2023-2030).

The osteogenesis imperfecta (OI) treatment market major players are engaged in research & development to create innovative drugs and cutting-edge therapies. During the projected period, it is anticipated that the market strategic collaborative research and medication designation approvals would considerably fuel market expansion and generate vast development potential. For instance, on June 05 2023, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products, and Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced data from the dose-selection Phase 2 portion of the Phase 2/3 Orbit study showing that setrusumab rapidly induced bone production in OI-affected patients. Across all patients evaluated setrusumab demonstrated statistically significant increases in levels of serum P1NP (the N-terminal propeptide of type I procollagen), a sensitive marker of bone formation, and a substantial and significant improvement in bone mineral density (BMD) by 3 months.

Rising demand for novel therapies for osteogenesis imperfecta treatment

Rising demand for novel therapies for osteogenesis imperfecta treatment is expected to the growth of global osteogenesis imperfecta market over the forecast period.

Strategic acquisition by the key market players

Strategic acquisition by the key market players to enhance the product portfolio by developing novel therapies is expected to drive the global osteogenesis imperfecta market over the forecast period.

Osteogenesis Imperfecta Treatment Market Report Coverage

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa

The global osteogenesis imperfecta treatment market report is segmented into drugs, route of administration, and region.

Among Drugs, the global osteogenesis imperfecta treatment market is segmented into teriparatide, denosumab, and others. Out of which, the denosumab segment is expected to dominate the market during the forecast period and this is because it has become a crucial treatment for cancer and other skeletal problems, including children skeletal diseases like OI.

Among Route of Administration, the global osteogenesis imperfecta treatment market is segmented into subcutaneous, intravenous, oral, and others. The intravenous segment is expected to dominate the market over the forecast period.

Global Osteogenesis Imperfecta Treatment Market- Key Developments

On July 06 2023, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products, announced that the first patients have been dosed in both of its late-stage clinical trials evaluating setrusumab in pediatric and young adult patients with OI sub-types I, III, and IV.